US 11,987,632 B2
Antibodies binding to HLA-A2/MAGE-A4
Tina Weinzierl, Remetschwil (CH); Lydia Jasmin Hanisch, Birmensdorf (CH); Alexander Bujotzek, Munich (DE); Alejandro Carpy Gutierrez Cirlos, Munich (DE); Stefan Klostermann, Neuried (DE); Christian Klein, Bonstetten (CH); Simon Patrick Keiser, Aarau (CH); Tanja Fauti, Zurich (CH); Estelle Marrer-Berger, Basel (CH); and Pablo Umaña, Wollerau (CH)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Dec. 17, 2020, as Appl. No. 17/125,500.
Claims priority of application No. 19217463 (EP), filed on Dec. 18, 2019.
Prior Publication US 2021/0230278 A1, Jul. 29, 2021
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2833 (2013.01) [A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)] 68 Claims
 
1. An antibody that binds to HLA-A2/MAGE-A4, wherein the antibody comprises a first antigen binding domain, comprising a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 comprising the amino acid sequence of SEQ ID NO: 25, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 26, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 27, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 comprising the amino acid sequence of SEQ ID NO: 28, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 29, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 30.